Page last updated: 2024-09-03

marimastat and Neoplasms

marimastat has been researched along with Neoplasms in 27 studies

Research

Studies (27)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (37.04)	18.2507
2000's	15 (55.56)	29.6817
2010's	1 (3.70)	24.3611
2020's	1 (3.70)	2.80

Authors

Authors	Studies
DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR	1
Anceschi, C; Chiarugi, P; Chillà, A; De Palma, G; Del Rosso, M; Del Rosso, T; Fibbi, G; Frediani, E; Laurenzana, A; Margheri, F; Pelagio, G; Scavone, F; Tufaro, A	1
Cho, SH; Duin, EC; Hong, JW; Jambovane, S; Kim, SK; Yun, JY	1
Augustin, HG	1
Goodin, S; Gounder, M; Lin, Y; Medina, M; Much, J; Musanti, R; Orlando, T; Pennick, M; Rubin, E; Shih, W; Toppmeyer, DL; Vyas, V	1
Muehlbauer, PM	1
Peterson, JT	1
Balkwill, F; Blann, AD; Caine, GJ; Christodoulos, K; Dobbs, N; Ganesan, TS; Gompertz, N; Harris, AL; Jones, PH; Kakkar, AJ; Kumar, S; Talbot, DC; Thavasu, P	1
Didziapetriene, J; Kadziauskas, J; Stanciūte, D	1
Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY	1
Kuwano, M; Ono, M	2
Dickson, RB; Hawkins, MJ; Wojtowicz-Praga, SM	1
Brown, PD	1
Denis, LJ; Verweij, J	1
Berrington, A; Brown, P; Cornish, A; Cox, D; Kerr, D; Lynch, K; Malfetano, J; Millar, A; Nemunaitis, J; Poole, C; Primrose, J; Rasmussen, H; Rosemurgy, A	1
Davidson, S	1
Steward, WP	1
Bout, JC; Soncin, F; Vandenbunder, B	1
Fingleton, B; Matrisian, LM; Nelson, AR; Rothenberg, ML	1
Sone, S	1
Sasaki, Y; Tahara, M	1
Steward, WP; Thomas, AL	1
Eckhardt, SG; Hidalgo, M	1
Shiraga, M; Sone, S	1
Bergen, M; Eckhardt, SG; Hidalgo, M; Holden, SN; Pierson, AS	1

Reviews

17 review(s) available for marimastat and Neoplasms

Article	Year
Current perspective of TACE inhibitors: a review. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: ADAM Proteins; ADAM17 Protein; Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Models, Molecular; Neoplasms; Structure-Activity Relationship	2009
[Angiogenesis research--quo vadis?]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2003, Volume: 100, Issue:2 Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Cell Communication; Drug Evaluation, Preclinical; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Ephrins; Forecasting; Growth Substances; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Lymphokines; Metalloendopeptidases; Mice; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research; Signal Transduction; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Anti-angiogenesis in cancer therapy. Seminars in oncology nursing, 2003, Volume: 19, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Lymphokines; Neoplasms; Oncology Nursing; Thalidomide; Tissue Extracts; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart failure reviews, 2004, Volume: 9, Issue:1 Topics: Cardiomyopathy, Dilated; Collagen; Doxycycline; Drug Design; Enzyme Activation; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Musculoskeletal Diseases; Myocardium; Neoplasms; Periodontal Diseases	2004
[Expression of matrix metalloproteinases in patients with malignant tumors]. Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases	2004
[Development of anti tumor agents targeting angiogenesis]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured	1997
Matrix metalloproteinase inhibitors. Investigational new drugs, 1997, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Down-Regulation; Drugs, Investigational; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydroxamic Acids; Metalloendopeptidases; Molecular Weight; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Protease Inhibitors; Protein Kinase C; Proteins; Thiophenes; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases	1997
Matrix metalloproteinase inhibitors in the treatment of cancer. Medical oncology (Northwood, London, England), 1997, Volume: 14, Issue:1 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms	1997
Matrix metalloproteinase inhibitors: present achievements and future prospects. Investigational new drugs, 1997, Volume: 15, Issue:3 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Extracellular Matrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neoplasms; Phenylalanine; Protease Inhibitors; Thiophenes	1997
[Neovascularization and tumor development]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Aug-10, Volume: 87, Issue:8 Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatins; Humans; Hydroxamic Acids; Interferons; Interleukin-12; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Phenylalanine; Plasminogen; Sesquiterpenes; Thalidomide; Thiophenes	1998
Marimastat (BB2516): current status of development. Cancer chemotherapy and pharmacology, 1999, Volume: 43 Suppl Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms	1999
[Clinical development of new molecular targeted therapeutics for cancer therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:8 Topics: Angiogenesis Inhibitors; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Hydroxamic Acids; Neoplasms	2000
[Dose escalation strategies of molecular target drugs]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:11 Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasms	2000
Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert opinion on investigational drugs, 2000, Volume: 9, Issue:12 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasms	2000
Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute, 2001, Feb-07, Volume: 93, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes	2001
[Matrix metalloproteinase inhibitors for therapy of cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Treatment Outcome	2001
Therapeutic angiogenesis inhibitors in the treatment of cancer. Advances in internal medicine, 2001, Volume: 47 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Collagen; Endostatins; Endothelial Growth Factors; Enzyme Inhibitors; Estradiol; Humans; Hydroxamic Acids; Lymphokines; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Peptide Fragments; Protein-Tyrosine Kinases; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001

Trials

3 trial(s) available for marimastat and Neoplasms

Article	Year
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Structure; Neoplasms; Paclitaxel	2003
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. British journal of cancer, 2004, Jul-05, Volume: 91, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; Dalteparin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Hydroxamic Acids; Injections, Subcutaneous; Lymphocytes; Male; Middle Aged; Neoplasms; Phytohemagglutinins; Treatment Outcome; Tumor Necrosis Factor-alpha	2004
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Staging; Neoplasms; Survival Rate	1998

Other Studies

7 other study(ies) available for marimastat and Neoplasms

Article	Year
Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling. Journal of translational medicine, 2023, 02-09, Volume: 21, Issue:1 Topics: Amoeba; Angiogenesis Inhibitors; Animals; Endothelial Cells; Female; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice; Morphogenesis; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A	2023
Log-scale dose response of inhibitors on a chip. Analytical chemistry, 2011, Aug-15, Volume: 83, Issue:16 Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Kinetics; Lab-On-A-Chip Devices; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Microchip Analytical Procedures; Neoplasms; Phenylalanine; Sensitivity and Specificity; Spectrometry, Fluorescence; Thiophenes	2011
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer. Cancer letters, 2005, Mar-10, Volume: 219, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A	2005
Is British Biotech's Marimastat a major cancer drug? Nature biotechnology, 1996, Volume: 14, Issue:7 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hydroxamic Acids; Investments; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasms; United Kingdom	1996
Marimastat. BB 2516, TA 2516. Drugs in R&D, 1999, Volume: 1, Issue:2 Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Hydroxamic Acids; Male; Melanoma; Metalloendopeptidases; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Stomach Neoplasms	1999
[Therapeutic prospects of angiogenesis inhibitors in cancerology]. Revue des maladies respiratoires, 1999, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Collagen; Endostatins; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Protease Inhibitors; Randomized Controlled Trials as Topic	1999
Matrix metalloproteinases: biologic activity and clinical implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals	2000